铂耐药卵巢癌患者再次接受铂类化疗的队列研究
单中心回顾性队列研究纳入30例高级别卵巢癌患者,均在至少一种非铂方案治疗铂耐药疾病后进展,自2010年1月至2024年6月在意大利欧洲肿瘤研究所接受铂类再挑战。客观缓解率27%(95%CI 12-46%),疾病控制率80%(95%CI 61-92%),中位随访14.1个月后中位无进展生存期5.4个月(95%CI 2.5-8.2),6个月无进展生存率47%(95%CI 28-63%)。作者认为铂类再挑战可作为特定铂耐药卵巢癌患者的可行治疗选择。
要点
- 30例铂耐药后接受非铂方案进展的高级别卵巢癌患者中,23例(77%)再挑战用卡铂、7例(23%)用顺铂。
- 客观缓解率27%(95%CI 12-46%),疾病控制率80%(95%CI 61-92%)。
- 中位无进展生存期5.4个月(95%CI 2.5-8.2),6个月无进展生存率47%(95%CI 28-63%)。
核心结论
- 铂类再挑战可作为特定铂耐药卵巢癌患者(既往接受过非铂方案)的可行治疗选择;本研究提示可在患者治疗史中动态重新评估铂类是否仍是最佳选择。
研究设计与样本
- 单中心、回顾性队列研究,纳入2010年1月至2024年6月在意大利欧洲肿瘤研究所治疗的高级别卵巢癌患者,均在至少一种非铂方案治疗铂耐药疾病后进展,共30例。
- 样本量30例可估计6个月无进展生存率为30%,95%CI为14%至47%。
主要发现
- 30例患者中23例(77%)接受卡铂再挑战,7例(23%)接受顺铂再挑战;既往治疗线数中位数为3(四分位距3-4)。
- 客观缓解率为27%(95%CI 12-46%),疾病控制率为80%(95%CI 61-92%)。
- 中位随访14.1个月(范围3.3-52.7)后,中位无进展生存期为5.4个月(95%CI 2.5-8.2),6个月无进展生存率为47%(95%CI 28-63%)。
关键数值与推荐
- 2018年ESMO-ESGO卵巢癌共识会议推荐:铂耐药疾病患者在接受非铂方案治疗后,若既往铂类治疗期间未进展,可考虑铂类再挑战。
临床怎么用
- 对于既往铂类治疗期间未进展、铂耐药后已接受非铂方案治疗的高级别卵巢癌患者,可考虑铂类再挑战;作者认为可在治疗史中动态重新评估铂类是否仍为最佳选择。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: According to the 2018 ESMO-ESGO consensus conference recommendations on ovarian cancer, platinum rechallenge could be considered in patients with platinum-resistant disease following a treatment with a non‑platinum regimen, if they had not progressed during prior platinum therapy. However, few data are available in this specific setting, especially after the incorporation of novel agents in the current treatment algorithm for ovarian cancer. METHODS: We conducted a single-center, retrospective, cohort study to evaluate the activity of platinum rechallenge in patients with high-grade ovarian cancer, progressing on at least one non‑platinum regimen for platinum-resistant disease, from January 2010 to June 2024, at the European Institute of Oncology (Italy). A sample size of 30 patients allowed to estimate a 6-month progression-free survival (PFS) rate of 30 %, with a 95 % confidence interval (CI) ranging from 14 % to 47 %. RESULTS: 30 patients were included: 23 (77 %) received rechallenge with carboplatin and 7 (23 %) with cisplatin. The median number of previous treatment lines was 3 (interquartile range: 3-4). The objective response rate was 27 % (95 % CI: 12-46 %) and the disease control rate was 80 % (95 % CI: 61-92). After a median follow-up of 14.1 months (range: 3.3-52.7), the median PFS was 5.4 months (95 % CI: 2.5-8.2) and the 6-month PFS rate was 47 % (95 % CI: 28-63 %). CONCLUSIONS: Platinum rechallenge can be a viable treatment option for selected patients with platinum-resistant ovarian cancer who have previously received a non‑platinum regimen. This study suggests that we could dynamically reassess whether platinum is the best option during the patient's treatment history.
引用
- Valenza C, Mongillo M, Visconti MV, et al. Rechallenge with platinum-based chemotherapy in patients with platinum-resistant ovarian carcinoma: A cohort study. Gynecol Oncol. 2025. PMID: 39923679. doi:10.1016/j.ygyno.2025.01.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。